AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06500247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpicilib
Description: This study recruited a total of 43 subjects diagnosed with Metastatic Castration-Resistant Prostate Cancer at multiple centers from July 2024. Enrolled patients received treatment with dalpicilib until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
Study NCT06500247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate (II)
Description: This study recruited a total of 43 subjects diagnosed with Metastatic Castration-Resistant Prostate Cancer at multiple centers from July 2024. Enrolled patients received treatment with Abiraterone Acetate (II) until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
Study NCT06500247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: This study recruited a total of 43 subjects diagnosed with mCRPC at multiple centers from July 2024. Enrolled patients received treatment with Androgen Deprivation Therapy until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
Study NCT06500247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: This study recruited a total of 43 subjects diagnosed with mCRPC at multiple centers from July 2024. Enrolled patients received treatment with Prednisone until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
Study NCT05642910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azvudine
Description: Patients received Azvudine orally, for 7 consecutive days (7 doses in total)
Study NCT05642910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxlovid group
Description: Patients received Paxlovid orally for 5 consecutive days (10 doses in total).
Study NCT05261204 — intervention group
Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Implantation
Description: Patients who are deemed receive TAVI first underwent evaluation of their peripheral arteries before the procedure, in order to separate those eligible for transfemoral placement (TFP) from those who would require transapical placement. Technological advances achieved in the new platforms for the treatment of SHD have allowed the use of reduced size catheters and sheaths in the new armamentarium, favoring the TFP technique. The transcatheter valve (TV) is positioned at the level of the native aortic valve during the final step of valve replacement, when the balloon is inflated within the native valve during a brief period of rapid ventricular pacing. The delivery system i traverses the aorta retrograde over a guidewire from its point of insertion in the femoral artery during the use of TFP. Before balloon inflation, the valve and balloon are collapsed on the catheter and fit within the sheath. After balloon inflation, the calcified native valve is replaced by the expanded TV
Study NCT05261204 — intervention group
Intervention type: PROCEDURE
Intervention: Bioprothesis
Description: The bioprosthesis is implanted using the SAVR procedure during median sternotomy in extracorporeal circulation. Minimally invasive procedures using a thoracotomy approach and peripheral cannulation have found widespread use.
Study NCT05261204 — intervention group
Intervention type: PROCEDURE
Intervention: Sutureless
Description: The sutureless is implanted using the SAVR procedure during median sternotomy in extracorporeal circulation. Minimally invasive procedures using a thoracotomy approach and peripheral cannulation have found widespread use.
Study NCT05519345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Operant Conditioning
Description: Active encouragement and feedback to increase motor evoked response during stimulation.
Study NCT05519345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Absence of active encouragement and feedback to increase motor evoked response when stimulated.
Study NCT06771245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYH9056
Description: PO once daily, 1 tablet each time, each tablet contains 2.5mg levamlodipine and 80mg valsartan
Study NCT06771245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYH9056
Description: PO once daily, 1 tablet each time, each tablet contains 2.5mg levamlodipine and 80mg valsartan
Study NCT05833672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terelizumab
Description: q3w Terelizumab 200mg on day 1 of each cycle
Study NCT05833672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CapeOx
Description: Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
Study NCT06538701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterolateral advancement pharyngoplasty
Description: Starting with bilateral tonsillectomy, The palatopharyngeal muscle (PPM) raised and advanced to be fixed to the pterygomandibular raphe, The posterior part of the PPM, together with its attached mucosa, was then advanced superolaterally behind the palatoglossus muscle to be hooked up to the levator veli palatini muscle
Study NCT06530979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tailored nutritional education program utilizing Saudi-sign language supplied by Saudi-sign language interpreter
Description: The program will be implemented in an experimental group composed of profoundly impaired hearing adults (91 Decibels and above). The experimental group will receive nutrition group counselling via photos, and models, and Saudi-sign language interpreter, including awareness of food groups and their nutrients, choose healthy and balanced items from supermarkets, restaurants or coffee shop menus-traffic lights on nutrition labelling and health problems or diseases related to diet and weight management
Study NCT06533995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visuprime
Description: Visuprime is a medical device (class IIa sterile) with ophtalmic indication, consisting on a 10 ml multidose bottle
Study NCT06533995 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo eyedrop isotonic buffered saline solution
Study NCT06771245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levamlodipine
Description: 2.5mg PO once daily
Study NCT06771245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamlodipine
Description: 2.5mg PO once daily
Study NCT06771245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 80mg PO once daily
Study NCT06771245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYH9056 placebo
Description: PO once daily
Study NCT06771245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamlodipine placebo
Description: PO once daily
Study NCT06771245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan placebo
Description: PO once daily
Study NCT05624463 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Modified intubation protocol
Description: 1. Turn on the electromyography (EMG) monitor and connect the EMG monitor to the patient as the patient is anesthetized; 2. View the vocal cords with video laryngoscope and intubate the patient with the EMG endotracheal tube; 3. Check the EMG monitor to confirm the correct contact between the electrodes and vocal cords; 4. Adjust the tube to achieve proper and stable contact between the electrodes and vocal cords; 5. Tape the EMG endotracheal tube at the midline and position the patient.
Study NCT05624463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified intubation protocol
Description: 1. Turn on the electromyography (EMG) monitor and connect the EMG monitor to the patient as the patient is anesthetized; 2. View the vocal cords with video laryngoscope and intubate the patient with the EMG endotracheal tube; 3. Check the EMG monitor to confirm the correct contact between the electrodes and vocal cords; 4. Adjust the tube to achieve proper and stable contact between the electrodes and vocal cords; 5. Tape the EMG endotracheal tube at the midline and position the patient.
Study NCT05624463 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conventional intubation protocol
Description: 1. Intubate the patient with the EMG endotracheal tube and note depth; 2. Position patient and verify the position via Glottic Exam or Respiratory Variation; 3. Fix tube position.
Study NCT05624463 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Early resumption of oral intake
Description: Patients will drink 30-50ml of normal temperature water after Steward scores ≥ 4 at PACU. If patients swallow successfully and have no significant discomfort symptoms, physicians will guide patients to resume drinking and eating gradually.
Study NCT05624463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early resumption of oral intake
Description: Patients will drink 30-50ml of normal temperature water after Steward scores ≥ 4 at PACU. If patients swallow successfully and have no significant discomfort symptoms, physicians will guide patients to resume drinking and eating gradually.
Study NCT05624463 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed resumption of oral intake
Description: Patients will resume drinking water 6h after the operation at ward. Before patients resume oral drinking, they will be provided 10ml/kg 5% glucose saline intravenously.
Study NCT05562154 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Ankle Replacement
Description: Participants will undergo either lateral approach or anterior approach when having a total ankle replacement
Study NCT06471582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artificially Sweetened Carbohydrate Beverage
Description: Beverage containing 0.7 g carbohydrate/ kg body mass/ h as a 2:1 mixture of glucose and fructose and artificial sweetener
Study NCT06471582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Artificially Sweetened Beverage
Description: Beverage containing no carbohydrates or kilocalories and an artificial sweetener
Study NCT05160935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Each patient will be informed about the study, and written consent will be obtained from patients who agree to participate in the study, explaining the purpose and duration of the study. A Patient Identification Form will be filled, the patient's vital signs will be evaluated, and the State-Trait Anxiety Inventory will be administered to the patient.~Before the coronary angiography procedure, the patients in the experimental group will be trained by the researchers using the training booklet. Trait Anxiety Inventory will be re-administered to the patients after the procedure. Vital signs of patients will be monitored.~In the control group; In line with the information in the patient consent form before the coronary angiography procedure, verbal information will be given about the coronary angiography procedure within the scope of the routine procedure in the clinic. After the procedure, the State-Trait Anxiety Inventory will be applied again. Vital signs will be taken.
Study NCT04765085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive behavioral intervention therapy (CBIT)
Description: Comprehensive behavioral intervention for tics is an extension of habit reversal training. It includes an expanded set of strategies, such as psycho-education about tic disorders, tic awareness training, competing response training, relaxation training, and functional analysis.~According to the CBIT treatment manual (translated by sun Jinhua and Xu Wen, the author were Douglas W. woods et al., Oxford University Press, New York). The treatments consisted of 8 sessions for 10 weeks The first two phases were 1.5 hours, the last six stages were 1 hour.The treatment process was regularly supervised by a treatment supervisor.
Study NCT04765085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole 5Mg Oral Tablet
Description: Considering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded
Study NCT05081284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volume-stable collagen matrix Geistlich Fibro-Gide®
Description: After tooth extraction and implant insertion the Test group will receive a soft tissue augmentation on the buccal side oh the implant. an envelop flap will be raised and a volume-stable collagen graft will be stabilized with sutures.~Control group will not receive soft tissue augmentation.
Study NCT06385704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DMR Procedure
Description: Endoscopic procedure
Study NCT06419764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spleen Invigorating and Weight Reducing Decoction
Description: Composition: Raw Astragalus (Huang Qi) 5g, Cang Zhu 5g, Fructus Aurantii Immaturus (Zhi Shi) 3g, Prepared Rhubarb (Shu Jun) 3g, Red Peony Root (Chi Shao Yao) 3g, Crataegus (Shan Zha) 3g, Tribulus (Bai Jie Li) 2g, Cimicifuga (Sheng Ma) 1g.~Granule form, for oral administration. Take 1 dose daily (2 bags, once in the morning and once in the evening, dissolved in water), for a course of 1 month.
Study NCT06419764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet and meal replacements
Description: The dietitian provides recommended meal plans based on body weight, and meal replacements are used postoperatively.
Study NCT06419764 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet and meal replacements
Description: The dietitian provides recommended meal plans based on body weight, and meal replacements are used postoperatively.
Study NCT05060757 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: biotax
Description: patients who are scheduled to undergo colonoscopy will be asked to participate and give a stool sample
Study NCT06773572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Exososomes procedure obtained from the patients' own platelets.
Description: Intraovarian injection (into the ovarian cortex) was performed over four cycles, once a month in each ovary on days 7, 8, or 9 of the menstrual cycle. Blood was drawn using the selected PRP kit; in this case, all the PRP was placed into two 20 cc syringes, and the exosomes were filtered using the EXOSMAT kit for autologous platelet exosomes. A total of 5 to 6 cc of liquid composed exclusively of platelet-derived exosomes was obtained, with a concentration of 5 to 6 trillion exosomes per milliliter. Finally, 2 to 3 cc were administered to each ovary via the transvaginal route.
Study NCT06773572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient group for activated platelet growth factors
Description: the plasma was placed in two 5 cc injectors to place 2 to 3 cc in each ovary (in the ovarian cortex) with the patient sedated. The PRP was placed transvaginally and using a follicular aspiration needle for the PRP group. All biostimulations were performed in early follicular phase (day 7, 8 or 9) in all groups according to their assigned technique.
Study NCT06269003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expert
Description: Participants will view a brief description of an expert source.
Study NCT06269003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer
Description: Participants will view a brief description of a peer source.
Study NCT06269003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 Sided
Description: Participants will view e-cigarette education messages in two-sided.
Study NCT06269003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 Sided
Description: Participants will view e-cigarette education messages in two-sided.
Study NCT01504282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitomycin-C
Study NCT01504282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: balanced salt solution (BSS)
Study NCT06500832 — intervention group
Intervention type: OTHER
Intervention: Survey-based Data Collection Tool
Description: The data collection tool to be presented to the participants is planned as a three-part survey. The first part of this form asked 9 questions about the demographic characteristics of the participants consisted of age, gender, marital status, duration in the profession, specialization in dentistry, type of workplace, and off-the-clock work.~The second part of the data collection tool consisted of the 'Defensive Dentistry Practice Survey,'(DDPS) DDPS which is the original language of which is Turkish, is a 5-point Likert-type scale. A total of 12 statements about DDPS which measure the opinions, attitudes, or behaviors of the participants in terms of DDP, the following options are used: strongly disagreed, disagreed, neither disagreed nor agreed, agreed and strongly agreed, each expressing groups of 20%.~The last part of the survey had 3 close-ended questions with yes-no options expressing 50% groups is used.
Study NCT06773572 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: the control group
Description: Finally, the control group received 2 to 3 cc of physiological solution in each ovarian cortex for 4 cycles as the two previous groups. All these procedures were performed transvaginally under controlled surgical sedation with follicular aspiration needle in the ovarian cortex and guided by transvaginal echosonogram
Study NCT05273580 — intervention group
Intervention type: DEVICE
Intervention: Garmin VivoSmart 4
Description: Wearable sensor to record; sleep, stress, heart rate etc.
Study NCT05273580 — intervention group
Intervention type: DEVICE
Intervention: mema - ilumivu
Description: mEMA is the a self-service platform running on both iOS and Android that is specifically designed for the administration of mobile Ecological Momentary Assessment or Experience Sampling research studies.
Study NCT05174000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Euthyrox®
Description: Participants will receive single oral dose of Test Euthyrox® either in treatment period 1, 2, 3 or 4.
Study NCT05174000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Euthyrox®
Description: Participants will receive single oral dose of Reference Euthyrox® either in treatment period 1, 2, 3 or 4.
Study NCT06282003 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The procedure of protective lung ventilation
Description: The procedure of protective lung ventilation in the PV group of patients included preoxygenation with 60% oxygen in a mixture with air for 3 min, which maintained the target peripheral oxygen saturation at values above 94%, endotracheal intubation, volume-controlled mechanical ventilation, a tidal volume of 6 ml per kg of body weight. Normocarbia during the protective ventilation procedure was maintained by adjusting the minute ventilation, which is the product of the respiratory rate (12-14 breaths per minute) and the tidal volume set to 6 ml/kg of body weight. The most critical variable for the adjustment was the inhalation-exhalation ratio of 1:2, which ensured adequate oxygenation and removal of carbon dioxide during anesthesia. Identically as in the PV group, the target peripheral saturation was kept above 94% with an inspiratory oxygen concentration of 50% and peak airway pressure values of up to 40 kPa.
Study NCT06282003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The procedure of protective lung ventilation
Description: The procedure of protective lung ventilation in the PV group of patients included preoxygenation with 60% oxygen in a mixture with air for 3 min, which maintained the target peripheral oxygen saturation at values above 94%, endotracheal intubation, volume-controlled mechanical ventilation, a tidal volume of 6 ml per kg of body weight. Normocarbia during the protective ventilation procedure was maintained by adjusting the minute ventilation, which is the product of the respiratory rate (12-14 breaths per minute) and the tidal volume set to 6 ml/kg of body weight. The most critical variable for the adjustment was the inhalation-exhalation ratio of 1:2, which ensured adequate oxygenation and removal of carbon dioxide during anesthesia. Identically as in the PV group, the target peripheral saturation was kept above 94% with an inspiratory oxygen concentration of 50% and peak airway pressure values of up to 40 kPa.
Study NCT04783636 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: leuprorelin acetate 3.75mg
Description: PT105, PT105R
Study NCT04991766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-LY3484356
Description: Administered orally.
Study NCT04991766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally.
Study NCT04991766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-LY3484356 (IV)
Description: Administered IV.
Study NCT06451432 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Inguinal Ring Suturing (PIRS) technique
Description: Percutaneous Inguinal Ring Suturing (PIRS) technique
Study NCT05094518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone reminders
Description: Appointment reminders in the form of push notifications will be sent through HERA app.
Study NCT06095648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dose of platelet transfusion
Description: Intervention is using a lower (5ml/kg) compared to usual (15ml/kg) dose of platelets for transfusion in non-bleeding babies born at or before 32 weeks in NICU